{
  "id": "602825a61cb411341a0000fa",
  "type": "list",
  "question": "Which drugs are included in the MAID chemotherapy regimen for sarcoma?",
  "ideal_answer": "MAID chemotherapy regimen for sarcomas include mesna, adriamycin, ifosfamide and dacarbazine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/12478905",
    "http://www.ncbi.nlm.nih.gov/pubmed/7672707",
    "http://www.ncbi.nlm.nih.gov/pubmed/11300337",
    "http://www.ncbi.nlm.nih.gov/pubmed/8951354",
    "http://www.ncbi.nlm.nih.gov/pubmed/2504890",
    "http://www.ncbi.nlm.nih.gov/pubmed/30032825",
    "http://www.ncbi.nlm.nih.gov/pubmed/10362334",
    "http://www.ncbi.nlm.nih.gov/pubmed/9529020",
    "http://www.ncbi.nlm.nih.gov/pubmed/12829150",
    "http://www.ncbi.nlm.nih.gov/pubmed/18313854",
    "http://www.ncbi.nlm.nih.gov/pubmed/32881345",
    "http://www.ncbi.nlm.nih.gov/pubmed/21652583",
    "http://www.ncbi.nlm.nih.gov/pubmed/32427061",
    "http://www.ncbi.nlm.nih.gov/pubmed/22179493",
    "http://www.ncbi.nlm.nih.gov/pubmed/24647783",
    "http://www.ncbi.nlm.nih.gov/pubmed/2050307",
    "http://www.ncbi.nlm.nih.gov/pubmed/2110385",
    "http://www.ncbi.nlm.nih.gov/pubmed/16446334",
    "http://www.ncbi.nlm.nih.gov/pubmed/31232921",
    "http://www.ncbi.nlm.nih.gov/pubmed/23092789",
    "http://www.ncbi.nlm.nih.gov/pubmed/12445253",
    "http://www.ncbi.nlm.nih.gov/pubmed/7595717"
  ],
  "snippets": [
    {
      "text": "Upon completion of 3 cycles of the MAID regimen (mesna, adriamycin, ifosfamide, dacarbazine), computed tomography showed disease progression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24647783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: Advanced STS patients aged 18-65 years received four courses of standard mesna, adryamycin, ifosfamide and dacarbazine (MAID) treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21652583",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "One randomized trial reported a significant improvement in overall survival for patients receiving doxorubicin and dacarbazine compared to those receiving a combination of doxorubicin, dacarbazine, and ifosfamide (MAID). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18313854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) was the most commonly used chemotherapy regimen as neoadjuvant or adjuvant treatment while ifosfamide (93.7%) was the most commonly used chemotherapy drug in any setting. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32881345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30032825",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "MATERIALS AND METHODS: The medical records of 17 patients who received mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) for advanced PC between January 2010 and February 2017 were retrospectively analyzed for clinicopathological features and outcomes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30032825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A regimen of pre-operative chemotherapy consisting of mesna, adriamycin, ifosfamide and dacarbazine (MAID), interdigitated with radiotherapy (RT), followed by resection and post-operative chemotherapy with or without RT, has demonstrated high rates of local and distant control. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23092789",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179493",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Our aim was to investigate the efficacy, feasibility and adverse effects of neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide and dacarbazine (MAID) regimen for NSRCSTSs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22179493",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The purpose of this clinical trial was to evaluate the efficacy and toxicity of MAID regimen (mesna/ifosfamide + Adriamycin + dacarbazine) in the treatment of advanced soft tissue sarcoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12478905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "THODS: This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma.RE",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9529020",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The MAID regimen was administered intravenously every 4 weeks in the hospital as follows: (1) mesna 1500 mg/m2/day x 4 days; (2) doxorubicin 15 mg/m2/day x 3 days; (3) ifosfamide 1500 mg/m2/day x 3 days; (4) dacarbazine 250 mg/m2/day x 3 days.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12445253",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12445253",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE: This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7595717",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e agents at present. The purpose of this clinical trial was to evaluate the efficacy and toxicity of MAID regimen (mesna/ifosfamide + Adriamycin + dacarbazine) in the treatment of advanced so",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12478905",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID). Startin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2504890",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID). Sta",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2504890",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2110385",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2504890",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Four patients with metastatic ovarian mixed M\u00fcllerian sarcoma (2 homologous, 2 heterologous) were treated with mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7672707",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " tumors. A regimen of preoperative chemotherapy consisting of mesna, adriamycin, ifosfamide, and dacarbazine (MAID) interdigitated with radiotherapy followed by resection and postoperative chemotherapy with or without radiotherapy was designed to improve treatment",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12829150",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This study was conducted to determine the maximum tolerated dose of an intensified MAID (mesna, adriamycin, ifosfamide, dacarbazine) regimen with the support of lenograstim in patients with advanced soft tissue sarcomas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10362334",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since dose intensity of doxorubicin is correlated with the clinical response of patients with soft tissue sarcomas and since doxorubicin dose intensity may be compromised in combination chemotherapy, we evaluated the use of recombinant granulocytemacrophage colony-stimulating factor (rGM-CSF) to ameliorate myelosuppression and allow doxorubicin dose escalation in a phase I trial utilizing the MAID combination [Mesna 2.5 g/m2/day x 4 days, Adriamycin (doxorubicin) 15 mg/m2/day x 4 days, ifosfamide 2.0 g/m2/day x 3 days, dacarbazine 250 mg/m2/day x 4 days; to be repeated every 21 days].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8951354",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "She was treated with mesna, ifosfamide, Adriamycin, and dacarbazine (MAID) chemotherapy and after one cycle of chemotherapy she had no evidence of tumor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/2050307",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "When diagnosed with pulmonary metastasis, the patient received combined chemotherapy regimen of MAID (mesna, adriamycin, ifosfamide and dacarbazine) for 6 cycles.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31232921",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients received three cycles of neoadjuvant chemotherapy (CT; modified mesna, doxorubicin, ifosfamide, and dacarbazine [MAID]), interdigitated preoperative radiation therapy (RT; 44 Gy administered in split courses), and three cycles of postoperative CT (modified MAID).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16446334",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report, to the best of our knowledge, the first case of myxofibrosarcoma successfully treated with mesna, pirarubicin, ifosfamide and dacarbazine (modified MAID) regimen. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32427061",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The authors report a case of a 57-year-old male with advanced SRCC who had a durable complete response after MAID (mesna, adriamycin, ifosfamide and dacarbazine) chemotherapy, and remains free of disease four years after completing treatment. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11300337",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "mesna, adriamycin, ifosfamide, dacarbazine"
}